Update shared on08 Oct 2025
Fair value Increased 4.90%UCB's analyst price target has been increased from €229.06 to €240.28. This change reflects improved revenue growth expectations and profit margins highlighted by recent analyst updates.
Analyst Commentary
Recent updates from bullish analysts highlight a notable uptick in optimism regarding UCB's future performance and valuation. Price targets have been raised by significant margins, which underscores confidence in the company’s prospects.
Bullish Takeaways- Bullish analysts have increased their price targets substantially, which reflects higher expectations for future share performance.
- Consensus remains positive on UCB's revenue growth outlook, which suggests improved execution or strong pipeline developments.
- Ongoing profitability improvements are anticipated and may drive stronger margins, supporting the upgraded valuations.
- Maintained buy and overweight ratings demonstrate continued confidence in UCB's strategic direction and capacity for outperformance in the sector.
What's in the News
- UCB Pharma and Tanner Pharma Group have partnered in Southeast Asia to expand access to innovative treatments for epilepsy patients. (Client Announcements)
- Three-year data from the BE HEARD trials show sustained improvements with BIMZELX in adults with moderate-to-severe hidradenitis suppurativa, including continued high response rates and improved quality of life. (Product-Related Announcements)
- New long-term data presented on BIMZELX in plaque psoriasis support ongoing use to achieve complete skin clearance and symptom relief. Monitoring for liver function and infection risk is advised. (Product-Related Announcements)
- The "Rheum for Improvement" survey reveals persistent unmet needs and misconceptions about psoriatic arthritis and axial spondyloarthritis. The findings emphasize the value of open dialogue and education among younger patients. (Product-Related Announcements)
- UCB SA has raised its full-year 2025 guidance, now expecting revenue of at least EUR 7 billion and core EPS of at least EUR 7.25. (Corporate Guidance Raised)
Valuation Changes
- Consensus Analyst Price Target has increased from €229.06 to €240.28, reflecting a higher valuation outlook.
- Revenue growth expectations have risen from 12.0% to 12.9%, suggesting a more optimistic forecast for top-line expansion.
- Net profit margin has improved slightly from 21.3% to 21.9%, indicating anticipated efficiency gains and profitability.
- The future P/E ratio remains stable, moving minimally from 25.09x to 25.11x.
- The discount rate remains unchanged at approximately 5.97%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.